Why the AnteoTech (ASX:ADO) share price is plummeting 23% on Friday

The company's shares can't seem to catch a break.

| More on:
shocked man with hands over his face with a declining graph in background representing falling CleanSpace share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key Points

  • AnteoTech shares sink on additional request for information by the TGA
  • The company submitted a performance report last week to the TGA
  • Study timeline date impacted by Omicron outbreak and staff shortage across healthcare system

The AnteoTech Ltd (ASX: ADO) share price is freefalling today regardless of the All Ordinaries (ASX: XAO) edging higher.

At the time of writing, the nanotechnology company's shares are down 23.81% to 24 cents. This brings its week's losses to a tad over 35% for shareholders.

In comparison, the broader ASX index is up 0.19% to 7,128.2 points.

AnteoTech receives additional request information

Investors are selling AnteoTech shares after digesting the company's update regarding its EuGeni Reader and COVID-19 Rapid Diagnostic Test (RDT).

In its release, AnteoTech received a request for further information for its COVID-19 RDT by the Therapeutic Goods Administration (TGA). This relates to the collection of additional clinical data, together with other aspects of information.

The latest update follows the company's submission last week providing a performance report of the RDT's detection of SARS-CoV-2 variants.

Currently, the TGA is collaborating with AnteoTech on how best to address the clinical data requirements.

Late last year, the company supplemented its EuGeni studies by conducting a prospective clinical trial at the Alfred Hospital and Burnet Institute in Melbourne. This was conducted through a prospective clinical trial to further evaluate the performance of the EuGeni SARS- CoV-2 Ag RDT.

AnteoTech stated that the trial could provide further data in which the TGA may need to meet the clinical data requirements.

However, due to the current Omicron outbreak and healthcare staff shortage, the study timeline has been pushed back.

About the AnteoTech share price

Despite today's heavy losses, the AnteoTech share price has advanced by more than 120% over the past 12 months.

The company's shares reached an 8-month high of 41.5 cents last week, before crashing back down.

Based on today's price, AnteoTech has a market capitalisation of roughly $473.78 million, with more than 1.97 billion shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A medical specialist holds a red heart connected via technology and artificial intelligence (AI)
Share Gainers

Guess which ASX biotech stock just rocketed 25% on big US news

Here are all the details.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Fundie bullish on CSL shares after praising the 'special business'

Earnings growth justifies current valuations, these experts say.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 healthcare stock is charging higher following FDA update

What is getting investors excited today? Let's find out.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Healthcare Shares

Should you buy CSL shares after recent weakness?

Does the dip present a buying opportunity?

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares up 25% in 2 days as Chemist Warehouse merger looks set

The deal continues to create tailwinds for Sigma shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

500 million reasons why ResMed shares are charging higher today

This growing company has big plans and is forecasting strong growth through to the end of the decade.

Read more »